Lima PM, Batista AN, Domínguez AC, Soriano GJL, Aldama MI, Concepción IR, Morales MD, Fleites CV

Language: Spanish
References: 0
Page:
PDF size: 224.43 Kb.

ABSTRACT

Background: Gastroenteropancreatic neuroendocrine tumors (NET-GEP) are very low incidence diseases, although they represent 70 % of all neuroendocrine tumors, and 2 % of all gastrointestinal tumors.
Objetives: To characterize clinical evolution, response to treatment, and overall survival in patients with NET-GEP.
Method: Longitudinal and retrospective study, with 88 patients diagnosed with NETGEP, who were diagnosed, treated, and followed at the "Hermanos Ameijeiras" Hospital between January 2008 and December 2014.
Results: The median age was 57 years (31;84), with predominance of female patients, ages between 50-69 years, normal nutritional status, ECOG 1-2, and symptomatic at diagnosis. Patients with a primary pancreatic site, well-differentiated carcinomas, G1, mixed histological pattern, and clinical stage IV predominated. 70 % of patients received surgery at diagnosis, and pancreatic and small bowel or colon resections account for 72 % of this. The variables with the worst rate of disease control and survival (OS) are: male sex, malnutrition, ECOG 3-4, neuroendocrine carcinoma, clinical stage IV, and no surgery at diagnosis (p <0.05). The histological grade G3 was statistically significant for SV, but not for the control of the disease. The OS rates obtained at 1.3, and 5 years are 71.1 %, 51.5 %, and 45.8 %, respectively, while the median OS was 66 months (54.24; 77.70).
Conclusions: This work is the first observational study on NET-GEP in Cuba, which includes results of the treatments in the so-called "real world" and the data provided will serve as a benchmark for comparison in the incorporation of new diagnostic and treatment technologies.